Clinical Trial Update: Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating belimumab added to B-cell depletion in relapsing-remitting multiple sclerosis was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Belimumab (belimumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2023-03-07